Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · Real-Time Price · USD
5.05
-0.17 (-3.26%)
Sep 8, 2026, 12:20 PM EDT - Market open
Champions Oncology Ratios and Metrics
Market cap in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
| 70 | 83 | 98 | 66 | 67 | 104 | |
Market Cap Growth | -26.76% | -15.55% | 48.65% | -1.17% | -35.77% | -27.72% |
Enterprise Value | 70 | 81 | 101 | 69 | 64 | 105 |
Last Close Price | 5.22 | 5.96 | 7.15 | 4.85 | 4.92 | 7.68 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
PE Ratio | - | - | 20.85 | - | - | 189.51 |
Forward PE | - | 114.60 | 119.17 | 64.10 | 43.81 | 42.95 |
PS Ratio | 1.22 | 1.39 | 1.72 | 1.32 | 1.24 | 2.12 |
PB Ratio | 18.40 | 20.35 | 25.98 | -34.65 | 14.39 | 11.42 |
P/TBV Ratio | 20.12 | 22.97 | 28.51 | - | 15.51 | 11.85 |
P/FCF Ratio | - | - | 14.01 | - | 60.64 | 25.25 |
P/OCF Ratio | - | - | 13.27 | - | 16.80 | 15.99 |
PEG Ratio | - | 4.27 | 4.27 | 4.27 | 2.92 | 2.86 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
EV/Sales Ratio | 1.22 | 1.36 | 1.78 | 1.38 | 1.19 | 2.13 |
EV/EBITDA Ratio | 207.62 | 231.99 | 15.65 | - | - | 46.90 |
EV/EBIT Ratio | - | - | 20.94 | - | - | 172.63 |
EV/FCF Ratio | - | - | 14.51 | - | 58.12 | 25.48 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Debt / Equity Ratio | 1.13 | 1.13 | 1.68 | -3.90 | 1.86 | 1.04 |
Debt / EBITDA Ratio | 2.16 | 2.16 | 0.77 | - | - | 2.29 |
Debt / FCF Ratio | - | - | 0.90 | - | 7.82 | 2.30 |
Net Debt / Equity Ratio | -0.07 | -0.07 | -0.92 | -2.53 | -0.33 | 0.05 |
Net Debt / EBITDA Ratio | -0.79 | -0.79 | -0.53 | -0.95 | 0.54 | 0.21 |
Net Debt / FCF Ratio | 0.05 | 0.05 | -0.49 | -0.69 | -1.38 | 0.11 |
Asset Turnover | 2.00 | 2.00 | 1.95 | 1.66 | 1.55 | 1.56 |
Quick Ratio | 0.91 | 0.91 | 0.88 | 0.56 | 0.83 | 1.06 |
Current Ratio | 0.97 | 0.97 | 0.94 | 0.63 | 0.90 | 1.13 |
Return on Equity (ROE) | -29.97% | -29.97% | 503.05% | -532.46% | -77.70% | 6.63% |
Return on Assets (ROA) | -2.17% | -2.17% | 10.36% | -14.31% | -7.98% | 1.21% |
Return on Invested Capital (ROIC) | -34.05% | -50.12% | 197.68% | -179.58% | -70.22% | 5.21% |
Return on Capital Employed (ROCE) | -14.60% | -14.60% | 57.10% | -150.80% | -35.40% | 3.40% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Earnings Yield | -1.62% | -1.42% | 4.80% | -11.04% | -8.00% | 0.53% |
FCF Yield | -6.94% | -6.08% | 7.14% | -10.58% | 1.65% | 3.96% |
Buyback Yield / Dilution | 3.04% | 3.04% | -5.31% | -0.04% | 4.37% | 2.84% |